Effectiveness of HPV vaccine by age at vaccination and number of doses: protocol for a population-based matched case-control study.

ABSTRACT:

Introduction

In 2006, the first human papillomavirus (HPV) vaccine was approved by the Food and Drug Administration in the USA based on pre-licensure clinical trials that found it to be highly efficacious at preventing persistent infection and precancerous, high-grade cervical lesions (HGCLs) caused by viral types the vaccine protects against. However, the real-world effectiveness of HPV vaccines as used in clinical practice may be quite different from the efficacy found in pre-licensure clinical trials. More than 10 years have passed since the introduction of the vaccine programme. It is critical to determine if the full benefits of HPV are being realised in real-world settings.

Methods and analysis

The objectives of this study were to estimate the effectiveness of HPV vacc

SUBMITTER: Oliveira CR 

PROVIDER: S-EPMC8057558 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature